Celgene Korea received sales approval of multiple myeloma treatment 'Pomalyst'

On August 4, Celgene Korea, a global pharmaceutical company specializing in cancer areas received sales approval of multiple myeloma treatment 'Pomalyst (ingredient pomalidomide)' from the Ministry of Food and Drug Safety. 'Pomalyst' received sales approval with the indication dexamethasone combination therapy for the treatment of recurrence and refractory multiple myeloma patients who previous...